JGH OPEN: TNF-alpha inhibitors effectively reduce the incidence of emergency events in patients with inflammatory bowel disease

Background and objective: Severe ulcerative colitis (UC) can be life-threateningTNF-alpha inhibitors (inphylixiasmone) are special drugs for the treatment of acute severity OFUCThe purpose of this study was to assess the efficacy of infexigotizumab in the prevention of sudden and emergency situations in patients with moderate to severe diseasesmethod: This is a retrospective cohort study of all patients treated at Royal Perth Hospital between 2002 and 2017Patients were divided into two queues: patients admitted to hospital before the introduction of infrasizumab (before 2008)The researchers compared two groups of data, including age, gender, length of hospital stay, use of infliath, colonectomy, and surgical complicationsEmergency surgery is defined as requiring surgery during admission, rather than emergency surgery, which is performed within 54 weeks of onsetResults: This study analyzed 313 UC cases from 2002 to 2017In the post-2008 queue, the rate of emergency surgery decreased from 19.4% to 8% (P-0.008)In addition, the proportion of operations performed as an emergency decreased from 36 per cent to 20 per centThis resulted in a significant reduction in hospital stay (13.4 days to 9.7 days, P 0.05) and complication incidence (36% to 20%, P-0.05)conclusion: Overall, with the addition of infrasily, the need for emergency and emergency treatment in UC patients has been significantly reduced, and this study has also confirmed the efficacy of infeoxion in reducing colonremoval rates